The Association for Clinical Oncology (ASCO) opposes the Most Favored Nation (MFN) Model for Medicare Part B drug reimbursement, which outlines a structured, nationwide, mandatory demonstration that will be phased in over four years, with full implementation for the final three years of the seven-year model. This plan effectively overrides a statutory provision under the guise of a demonstration project by imposing a new reimbursement model on cancer care absent any evidence that it can lower costs without negative consequences for Medicare beneficiaries.
As part of its ongoing commitment to addressing inequities in cancer care and research, the American Society of Clinical Oncology (ASCO) is launching a new educational series focused on the role of social determinants of health in cancer care and cancer outcomes. The free series, which kicks off today, will help educate oncology trainees and early career oncologists about social determinants of health and their impact on patients and cancer care.
Oncology providers familiar with the American Society of Clinical Oncology’s (ASCO) guideline on older adults with cancer are two to four times more likely to conduct a geriatric assessment on patients with cancer over the age of 65, according to the first international ASCO survey aimed at determining if and how often cancer providers are using geriatric assessments when treating older adults. This is a noteworthy finding, according to ASCO, because nearly 70% of patients with cancer in the United States are 65 years of age or older, and globally, the number of new cancer cases per year among older adults will exceed 13 million by 2030.
During the peak of the COVID-19 pandemic, fewer Black and Hispanic patients with cancer used telehealth (including phone encounters and video visits) as compared with white patients according to findings from an analysis of data from New York City hospitals. Significant disparities in the use of telehealth not only limit access to quality cancer care for these patients during the pandemic but will continue to hinder patient care as telehealth use becomes more integrated into standard cancer care. The study will be presented as part of the virtual 2020 ASCO Quality Care Symposium.
A study of more than 500 patients with cancer and COVID-19 at a large cancer center in Boston found that Black patients with cancer and COVID-19 were twice as likely to be hospitalized due to complications related to the virus as compared with white patients. Black patients were at greater risk of a visit to the emergency room. The findings will be presented at the upcoming virtual 2020 American Society of Clinical Oncology (ASCO) Quality Care Symposium.
Black and Hispanic patients with cancer were more likely to be infected with COVID-19 than white patients, based on the findings of a study of more than 477,000 patients with cancer. The study will be presented at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place virtually October 9–10, 2020.
Two-thirds of Americans report that their scheduled cancer screenings, such as mammograms and colonoscopies, have been delayed or skipped in the midst of the COVID-19 crisis, according to the American Society of Clinical Oncology (ASCO)’s fourth annual National Cancer Opinion Survey.
ASCO applauds Senators Richard Burr (R-NC) and Ben Cardin (D-MD) for introducing bipartisan legislation to expand access to clinical trials and improve the quality of cancer research. The CLINICAL TREATMENT Act (S. 4742) would require Medicaid to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Carolyn Hendricks, MD, FASCO, for her exceptional contributions and commitment to the Association’s advocacy efforts.
The Association for Clinical Oncology (ASCO) today presented Representative Rosa DeLauro (CT-3) with the annual Congressional Champion for Cancer Care Award in recognition of her exceptional commitment to bipartisan support for cancer research and treatment. The award honors a Member of Congress who is a leading champion for patients and survivors of cancer, their families, and their cancer care teams.
The Association for Clinical Oncology (ASCO) today released a statement regarding concerns that the U.S. Department of Health and Human Services (HHS) rescission of all guidance and informal issuances related to the Food and Drug Administration’s (FDA) current oversight of the premarket review and approval process for laboratory developed tests (LDTs) puts the safety of cancer treatments at risk.
The Association for Clinical Oncology (ASCO) today released a statement applauding the implementation of the Research to Accelerate Cures and Equity (RACE) for Children Act. As of today, applications to the Food and Drug Administration for marketing approval of new drugs and biological products—including orphan drugs that have relevance to pediatric cancer—must include an assessment of pediatric use.
The American Society of Clinical Oncology released today a position statement that recommends specific actions for applying telemedicine in cancer care during the pandenic and after its expiration.
One of the nation’s leading cancer organizations today called for new actions to reduce disparities in cancer outcomes affecting racial and ethnic minorities, rural populations, sexual and gender minorities, people without insurance, and other disadvantaged populations. In a policy statement published in the Journal of Clinical Oncology (JCO), the American Society of Clinical Oncology (ASCO) argues that while progress has been made in raising awareness of disparities and driving research, the cancer community needs to take bolder, more aggressive steps to achieve equity for all patients.
The American Society of Clinical Oncology (ASCO) released a position statement that raises concerns about home infusion of anticancer therapy and Centers for Medicare & Medicaid Services (CMS) regulations regarding the practice.